Evidence map›Paper›PMID 31841269›Full record

ArticleThoracic cancer2020

Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.

Seongho Park, Yoo-Duk Choi, Jieun Kim, Bo-Gun Kho, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Association betweenThe British journal of radiology · 2021
    Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Seongho ParkDepartment of Internal Medicine, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Yoo-Duk ChoiDepartment of Pathology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Jieun KimDepartment of Internal Medicine, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Bo-Gun KhoDepartment of Internal Medicine, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Cheol-Kyu ParkDepartment of Internal Medicine, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
In-Jae OhDepartment of Internal Medicine, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Young-Chul KimDepartment of Internal Medicine, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Chonnam National University Hwasun Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe correlated the tumor proportion score (TPS) of programmed cell death ligand 1 (PD-L1, SP263 or 22C3) expression with the disease control rate (DCR, partial remission and stable disease), and progression free survival (PFS) after nivolumab or pembrolizumab treatment.

methodsA total of 70 case records (55 males, 15 females) of patients with non-small cell lung cancer (NSCLC, 46 adenocarcinoma, 22 squamous cell carcinoma, and two others) were reviewed. The PD-L1 expressions were divided into High (SP263 ≥ 30%, 22C3 ≥ 80%) and Low groups (SP263 < 30%, 22C3 < 80%). In the combined analysis, the PD-L1 group was defined as High if either of the two stains was classified as High and defined as Low if both stains were classified as Low.

resultsAmong the patients treated with nivolumab (n = 37), the SP263 High group showed higher DCR compared to the SP263 Low group (52.6% vs. 11.1%, P = 0.024). In patients treated with pembrolizumab (n = 33), no significant difference in DCR and PFS according to PD-L1 expression was observed. In the combined analysis (n = 36), patients in the PD-L1 High group showed significantly higher DCRs than those in the PD-L1 Low group (56.1% vs. 24.1%, P = 0.028). PFS was significantly longer in the PD-L1 High group than in the Low group (medians 4.1 vs. 1.6 months, respectively, P = 0.04).

conclusionA high expression level of PD-L1 was correlated with a significantly higher DCR and longer PFS in NSCLC patients treated with nivolumab or pembrolizumab.

Indexed as

Adenocarcinoma of LungAgedB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellFemaleFollow-Up StudiesHumansImmune Checkpoint InhibitorsLung NeoplasmsMalePrognosisRetrospective StudiesSurvival RateB7-H1 AntigenBiomarkers, TumorCD274 protein, humanImmune Checkpoint InhibitorsNivolumabnon-small cell lung cancerpembrolizumabprogrammed cell death ligand 1

Identifiers

PMID31841269
PMCPMC6996995
OpenAlexW2995996008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.